



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	102.65
Trade Time:	4:15 PM ET Jan 19, 2018
Change:	0.93 (0.914%)
Day Range	102.00 - 103.05
52-Week Range	94.55 - 147.17
Volume	8,112,136

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 19, 2018
[Investigational Data Presented at ASCO GI Evaluate ABRAXANE[®] Regimen for Patients with Locally Advanced Pancreatic Cancer](#)

Jan 8, 2018
[Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance](#)

Jan 7, 2018
[Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies](#)

Jan 3, 2018
[Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018](#)

Jan 2, 2018
[Celgene Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

Jan 25, 2018 9:00 AM ET
[Celgene Corporation Q4 2017 Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)